30 January 2021 : Clinical Research
Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
Naibo Hu12DE, Tiejun Qin1B, Xiaoyan Du3C, Bingyi Wang3DE, Xiaoyun Wang3E, Zefeng Xu1DF, Lijuan Pan1F, Shiqiang Qu1DF, Zhijian Xiao1A*DOI: 10.12659/MSM.928454
Med Sci Monit 2021; 27:e928454
Table 4 Toxicity analysis.
| Adverse events | Total (n=158) | Azacitidine (n=38) | Decitabine (n=120) | P value |
|---|---|---|---|---|
| Neutropenia | 93 (58.9%) | 16 (42.1%) | 77 (64.2%) | 0.016* |
| Thrombocytopenia | 97 (61.4%) | 19 (50.0%) | 78 (65.0%) | 0.098 |
| 38 (24.1%) | 8 (21.1%) | 30 (25.0%) | 0.620 | |
| 42 (26.6%) | 5 (13.2%) | 37 (30.8%) | 0.032* | |
| 3 (1.9%) | 0 (0.0%) | 3 (2.5%) | 0.999 | |
| 8 (5.1%) | 61 (2.6%) | 7 (5.8%) | 0.681 | |
| * | ||||